A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
NCT04933695
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
Sotorasib
Sponsor
Amgen